Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty

Transcultural Psychiatry

Volumn 46, Issue 1, 2009, Pages 180-206

  Leibing, Annette ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alzheimer medications; anthropology of uncertainty; efficacy

Indexed keywords

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANTHROPOLOGY, CULTURAL; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BRAZIL; CHOLINESTERASE INHIBITORS; DIFFUSION OF INNOVATION; DRUG INDUSTRY; DRUG PRESCRIPTIONS; GERIATRIC PSYCHIATRY; HUMANS; NOOTROPIC AGENTS; QUALITY OF LIFE; SOCIAL MARKETING; TREATMENT OUTCOME; UNCERTAINTY;

EID: 63049133985     PISSN: 13634615     EISSN: None     Source Type: Journal    
DOI: 10.1177/1363461509102297     Document Type: Article

References (86)

1. Achenbaum, W.A. (1995). Crossing frontiers, gerontology emerges as a science. Cambridge: Cambridge University Press.
2. Alzheimer's Disease International. (ADI). (2007). Fact sheet on unusual behaviour. Available: http://www.alzheimers.org.uk/Caring_for_someone_with_dementia/Unusual_behaviour/advice_drugsbehaviour.htm.
3. Alzheimer's Disease Research Center. (ADRC). (2006). Medications. Memory and Aging. San Francisco: University of California Press. Available: http://memory.ucsf.edu/Education/Treatment/medications.html.
4. Angell, M. (2000). The pharmaceutical industry: To whom is it countable? New England Journal of Medicine, 342(25): 1902-1904, 2000.
5. Ballard, C., & Cream, J. (2005). Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? International Psychogeriatrics, 17(1): 4-12.
6. Bauman, Z. (1992). Mortality, immortality and other life strategies. Stanford, CA: Stanford University Press.
7. Bauman, Z. (1995). Modernidade e Ambivalência, trans. Marcus Penschel. Rio de Janeiro: Jorge Zahar. (orig. Modernity and Ambivalence, 1991)
8. Beck, U. (1997). A reinvenção da política: Rumo a uma teoria da modernização reflexiva. In A. Giddens, U. Beck, & S. Lash (Eds.), Modernização reflexiva, trans. Magda Lopes (pp. 11–72). São Paulo, Brazil: Unesp. (orig. Reflexive modernization: Politics, tradition and aesthetics in the modern social order, 1995)
9. Berrios, G.E. (1989). Non-cognitive symptoms and the diagnosis of dementia: Historical and clinical aspects. British Journal of Psychiatry, 154(suppl.4): 11-16.
10. Berrios, G. (1990). Memory and the cognitive paradigm of dementia during the 19th century: A conceptual history. In R. M. Murray & T. H. Turner (Eds.), Lectures on the history of psychiatry, The Squibb series (pp. 194–211). London: Gaskell.
11. Betz, M., & O'Connell, L. (2003). Changing doctor-patient relationships and the rise in concern for accountability. In P. Conrad & V. Leiter (Eds.), Health and health care as social problems (pp. 317–330). Lanham, MD: Rowman & Littlefield.
12. Birks, J. (2005). Does Donepezil improve well-being for dementia due to Alzheimer's disease? (News from the Cochrane Neurological Network). Neuroepidemiology, 24, 168-169.
13. Birks, J., & Harvey, R. (2003). Donepezil for dementia due to Alzheimer's disease. Cochrane Database System Rev. 3.
14. Boholm, Å. (2003). The cultural nature of risk: Can there be an anthropology of uncertainty? Ethnos, 68(2), 159-178.
15. Bullock, R. (2005). Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Current Medical Research and Opinion, 21(1), 1-10.
16. Bursztajn, H.J., Feinbloom, R.I., Hamm, R.M., & Brodsky, A. (2000). Medical choices, medical chances: How patients, families, and physicians can cope with uncertainty. New York: iUniverse.
17. Castleman, M., Gallagher-Thompson, D., & Navthons, M. (1999). There's still a person in there: The complete guide to treating and coping with Alzheimer's. New York: Penguin.
18. Cohen-Mansfield, J., & Mintzer, J. (2005). Time for change: The role of non-pharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Disease & Associated Disorders, 19(1), 37-40.
19. Eastwood, R. (1997). Editorial: What's in a name? International Psychogeriatrics, 9(2), 107.
20. Finkel, S.I. (1996). New focus on behavioral and psychological signs and symptoms of dementia. International Psychogeriatrics, 8(suppl.3), 215-218.
21. Garcez-Leme, L.E., Leme, M.D., & Espino, D.V. (2005). Geriatrics in Brazil: A big country with big opportunities. Journal of the American Geriatrics Society, 53(11), 2018-2022.
22. Gauthier, S. (2002). Advances in the pharmacotherapy of Alzheimer's disease. Canadian Medical Association Journal, 166(5), 886.
23. Geldmacher, D.S., Frolich, L., Doody, R.S., Erkinjuntti, T., Vellas, B., Jones, R.W., Banerjee, S., Lin, P., & Sano, M. (2006). Realistic expectations for treatment success in Alzheimer's disease. Journal of Nutrition, Health & Aging, 10(5), 417-429.
24. Gill, S.S., Rochon, P.A., Herrmann, N., Lee, P.E., Sykora, K., Gunraj, N., Normand, S.L., Gurwitz, J.H., Marras, C., Wodchis, W.P., & Mamdani, M. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. British Medical Journal, 330(7489), 445. DOI: 10.1136/bmj.38330.470486.8F.
25. Goldsmith M. (1996). Hearing the voice of people with dementia: Opportunities and obstacles. London: Jessica Kingsley Publishers.
26. Grady, D. (2004, November 2). Alzheimer's steals more than memory. The New York Times.
27. Greene, J.A. (2007). Prescribing by numbers: Drugs and the definition of disease. Baltimore, MD: The Johns Hopkins University Press.
28. Greve, M., & O'Connor, D. (2005). A survey of Australian and New Zealand old age psychiatrists’ preferred medications to treat behavioral and psychological symptoms of dementia (BPSD). International Psychogeriatrics, 17(2), 195-205.
29. Gubrium, J.F. (1986). Oldtimers and Alzheimer's: The descriptive organization of senility. Greenwich, CT: Jai Press.
30. Harris, P.B. (2002). The person with Alzheimer's Disease: Pathways to understanding the experience. Baltimore, MD: Johns Hopkins University Press.
31. Harvard Mental Health Letter. (2004). Alzheimer's drugs: Are they worth it? November issue. Available: http://www.health.harvard.edu.
32. Healy, D. (2006). The latest mania: Selling Bipolar Disorder. PLoS Medicine, 3(4), e185, 1-4.
33. Hedgecoe, A.M. (2004). The politics of personalised medicine: Pharmacogenetics in the clinic. Cambridge: Cambridge University Press.
34. Iliffe, S., & Manthorpe, J. (2007). Following the trajectory of dementia: The NICE/SCIE guidelines. Dementia, 6(1), 7-9.
35. IPA (International Psychogeriatric Association). (1996a). Behavioral Approaches to the treatment of Alzheimer's Disease: Research strategies. T. S. Radebaugh, N. Buckholtz, & Z. Khachaturian (Guest Eds.). International Psychogeriatrics, 8(suppl.1), 7-12.
36. IPA (International Psychogeriatric Association). (1996b). Research methodologic issues in evaluating behavioral disturbances of dementia. S. I. Finkel (Guest Ed.). International Psychogeriatrics, 8(suppl.2), 149-150.
37. IPA (International Psychogeriatric Association). (1996c). Behavioral and psychological signs and symptoms of dementia: Implications for research and treatment. S. I. Finkel (Guest Ed.). International Psychogeriatrics, 8(suppl.3): 497-500.
38. IPA (International Psychogeriatric Association). (2000). Behavioral and psychological symptoms of dementia (BPSD): A clinical and research update. S. I. Finkel & A. Burns, (Guest Eds.). International Psychogeriatrics, 12(suppl.1): 19-21.
39. IPA (International Psychogeriatric Association). (2002). Behavioral and psychological symptoms of dementia (BPSD): Educational Pack. Skokie, IL: IPA.
40. Jackson, J. (2005). Dementia disaster. Alzheimer Scotland publications on-line. Available: http://www.alzscot.org/media/demdisaster.html.
41. Jürgs, M. (1999). Alzheimer. Spurensuche im Niemandsland. Frankfurt: List.
42. Katz, S., & Marshall, B. (2004). Is the functional ‘normal’? Aging, sexuality and the bio-marking of successful living. History of the Human Sciences, 17(1): 53-75.
43. Kerr, A., Cunningham-Burley, S., & Tutton, R. (2007). Exploring ambivalence about genetic research and its social context. Social Theory & Health, 5(1): 53-69.
44. Last, M. (2007). The importance of knowing about not knowing. In R. Littlewood (Ed.), On knowing and not knowing in the anthropology of medicine (pp. 1–17). Walnut Creek, CA: Left Coast Press.
45. Latour, B. (1999). Pandora's hope: Essays on the reality of science studies. Cambridge, MA: Harvard University Press.
46. Leibing, A. (2000). The history of Alzheimer's disease and its impact on senility in Brazil. Journal of the History of the Neurosciences, 9(2): 143-144.
47. Leibing, A. (2001). Marcinho et Mauricinho: Violence et les nouveaux héros de Rio de Janeiro, Brésil. Anthropologie et Sociétés, 25(3): 51-68.
48. Leibing, A. (2005). The old lady from Ipanema: Changing notions of old age in Brazil. Journal of Aging Studies, 19(1): 15-31.
49. Leibing, A. (2007). The hidden side of the moon, or, ‘lifting out’ in ethnographies. In A. McLean & A. Leibing (Eds.), The shadow side of fieldwork: Exploring the blurred borders between ethnography and life (pp. 138–156). Malden, MA: Blackwell Publishing.
50. Leibing, A. (2008a). Entangled matters - Alzheimer's, interiority, and the ‘un-flattening’ of the world. Culture, Medicine & Psychiatry, 32(2): 177-193.
51. Leibing, A. (2008b). Lessening the evils online: Embodied molecules and the politics of hope in Parkinson's disease. Manuscript submitted to Science Studies.
52. Leibing, A. (in press). From the periphery to the center: Treating behavioural and psychological symptoms in dementia. In J. Ballenger, P. Whitehouse, C. Lyketsos, P. Rabins, & J. Karlawish (Eds.), Do we have a pill for that? Interdisciplinary perspectives on the development, use and evaluation of drugs in the treatment of dementia. Baltimore, MD: The Johns Hopkins University Press.
53. Leibing, A., & Cohen, L. (Eds.). (2006). Thinking about dementia: Culture, loss, and the anthropology of senility. New York: Rutgers University Press.
54. Leibing, A., Coignard-Friedman, R., & Scheinkman, L. (2006). Mémoire défaillante - utilisation de médicaments et re-classification de la maladie d'Alzheimer. In J. Collin (Ed.), Le médicament au cœur de la socialité contemporaine: Regards croisés sur un objet complexe (pp. 177–196). Montreal, QC: Presses de l'Université du Québec.
55. Lenzer, J. (2005). FDA warns about using antipsychotic drugs for dementia. British Medical Journal, 330(23 April): 922.
56. Leuchter, A.F., Cook, I.A., Witte, E.A., Morgan, M. & Abrams, M. (2002). Changes in brain function of depressed subjects during treatment with placebo. American Journal of Psychiatry, 159(January): 122-129.
57. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., & Hsiao, J.K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12): 1209-1223.
58. Lima, M.G., Ribeiro, A.Q., Acurcio, F.de A., Rozenfeld, S., & Klein, C.H. (2007). Composição dos gastos privados com medicamentos utilizados por aposentados e pensionistas com idade igual ou superior a 60 anos em Belo Horizonte, Minas Gerais, Brasil. Cad. Saúde Pública, 23(6): 1423-1430. Available: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2007000600017&lng=pt&nrm=iso.
59. Maurer, K., & Maurer, U. (1998). Alzheimer, Das Leben eines Arztes und die Karriere einer Krankheit. Frankfurt: Piper.
60. McShane, R., & Gormley, N. (2002). Assessment and management of behavioural and psychological symptoms of dementia (BPSD). In J. Copeland, M. T. Abou-Saleh, & D. T. Blazer (Eds.), Geriatric psychiatry (pp. 241–244). Chichester: Wiley.
61. Miller, L.J. (2007). The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease. Consultant Pharmacist, 22(9), 754-762.
62. National Institute for Clinical Excellence, The. (NICE). 2001. Clinical and cost effectiveness of Donezepil, Rivastigmine, and Galantamine for Alzheimer's disease. Available: http://www.nice.org.uk/nicemedia/pdf/Alzheimer_hta.pdf, accessed May 2008.
63. National Institute for Clinical Excellence, The. (NICE). (2005). NICE appraisal of Alzheimer's drugs. Available: http://www.nice.org.uk/page.aspx?o=248137.
64. Petrovic, M., De Paepe, B., van Bortel, L. (2005). Pharmacotherapy of depression in old age. ACTA Clinica Belgia, 60(3): 150-156.
65. Piccini, W.J. (2002). Vivências em psicogeriatria: Uma contribuição para a história da psicogeriatria no Brasil tomando por base a produção científica coletada no Índice Bibliográfico Brasileiro de Psiquiatria. Psychiatry Online Brazil, 7. Available: http://www.polbr.med.br/arquivo/wal0302.htm.
66. Pilgrim, D. (2007). The survival of psychiatric diagnosis. Social Science and Medicine, 65(3): 536-547.
67. Potkin, S.G. (2002). The ABC of Alzheimer's disease: ADL and improving day-today functioning of patients. International Psychogeriatrics, 14(suppl.1): 7-26.
68. Prosser, H. & Walley, T. (2006). New drug prescribing by hospital doctors: The nature and meaning of knowledge. Social Science and Medicine, 62(7): 1565-1578.
69. Rabins, P.V., & Lyketsos, C.G. (2005). Antipsychotic drugs in dementia: What should be made of the risks? Journal of the American Medical Association, 294(15): 1963-1965.
70. Reisberg, B. (1981). A guide to Alzheimer's Disease. New York: The Free Press.
71. Research & Markets. (2007). Stakeholder insight: Alzheimer's disease - Prescription trends indicate that neurologists are not adhering to guidelines. Available: http:/www.researchandmarkets.com.
72. Rose, N. (2005). In search of certainty: Risk management in a biological age. Journal of Public Mental Health, 4(3): 14-22.
73. Royall, D.R. (2005). The emperor has no clothes: Dementia treatment on the eve of the aging era. Journal of the American Geriatric Society, 53(1): 163-164.
74. Sink, K.M., Holden, K.F., & Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. Journal of the American Medical Association, 293(5): 596-608.
75. Snyder, L. (1999). Speaking our minds: Personal reflections from individuals with Alzheimer's. Waterville, ME: Thorndike Press.
76. Spalletta, G., Baldinetti, F., Buccione, I., Fadda, L., Perri, R., Scalmana, S., Serra, L., & Caltagirone, C. (2004). Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. Journal of Neurology, 251(6): 688-695.
77. Szabo, J. (2002). Seeing is believing? The form and substance of French medical debates over Lourdes. Bulletin of the History of Medicine, 76(2): 199-230.
78. Therapeutics Initiative. (2005). Available: http://www.ti.ubc.ca/PDF/56.pdf.
79. Tighe, J.A. (1997). The legal art of psychiatric diagnosis. In C. E. Rosenberg & J. Golden (Eds.), Framing disease: Studies in cultural history (pp. 206–226). New Brunswick, NJ: Rutgers University Press.
80. Treloar, A., Beck, S., & Paton, C. (2001). Administering medicines to patients with dementia and other organic cognitive syndromes. Advances in Psychiatric Treatment, 7: 444-452.
81. Trinh, N.H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003). Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. Journal of the American Medical Association, 289(2): 210-216.
82. Van Melick, E.J. (2004). Atypical antipsychotics in the elderly. Tijdschrift Voor Gerontologie En Geriatrie, 35(6): 240-245.
83. Wahlberg, A. (2008). Above and beyond superstition: Western herbal medicine and the decriminalizing of placebo. History of the Human Sciences, 21(1): 77-101.
84. Wancata, J. (2004). Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. International Psychogeriatrs, 16(1): 107-115.
85. Whyte, S.R., van der Geest, S., & Hardon, A. (2002). Social lives of medicines. Cambridge, UK: Cambridge University Press.
86. Zinn, J.O. (2006). Recent developments in sociology of risk and uncertainty. Forum Qualitative Sozialforschung/Forum: Qualitative Social Research, 7(1). Available: http://www.qualitative-research.net/fqs-texte/1-06/06-1-30-e.htm.